Source: Annual Congress 2010 - COPD: treatment and monitoring
Disease area: Airway diseases

Abstract

Introduction: Systemic corticosteroids are routinely used for the treatment of acute exacerbation of COPD (AECOPD). Preliminary studies have demonstrated that nebulised budesonide to be as efficacious as parental steroids in AECOPD.
Objectives: To evaluate the clinical efficacy of nebulised budesonide with in AECOPD in comparison with parental steroids.
Materials and Methods: Patient‘s with AECOPD were included in the study and divided into two groups randomly. Control group who were given parental steroids and Study group received budesonide by nebulisation (2 mg every 12 hrly) for 5 days. These patients were assessed every 12 hrly from H₀ to H₇₂, day 5 and at discharge. The outcome variables studied were FVC, FEV₁, PEFR, dyspnea score, spO2 and SGRQ score. Both groups received standard treatment i.e. oxygen, salbutamol plus ipratropium by nebulisation and parental antibiotics during study period.
Results: A total of 125 patients were include in the study: 65 in study group and 60 in control group. The baseline FEV_1, FVC and PEFR were comparable in both groups. The mean improvement in FEV_{1 ,}FVC and PEFR after 24 hrs, 72 hrs and day 5 were nonsignificantly increased in both the groups. Similarly, improvements in oxygen saturation and dyspnea grade at day 5 showed no significance between the two groups. Patients in the study group showed better improvement in SGRQ score as compared to control group. Mean duration of hospitalization was less in study group as compared to control group.
Conclusion: Nebulised budesonide was equally as efficacious as parental steroids in AECOPD. Nebulised budesonide group had reduced duration of hospitalization and showed better improvement in SGRQ score as compared to control group.

Rating:

Share or cite this content

Citations should be made in the following way:
G. Gaude, S. Nemagouda (Belgaum, India). Clinical efficacy of nebulised budesonide in acute exacerbation of COPD. Eur Respir J 2010; 36: Suppl. 54, 1319

Member's Comments

No comment yet.

Related content which might interest you: The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007 Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 Efficacy and safety of intravenous montelukast in patients with acute exacerbations of bronchial asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Comparison of different dosage nebulised budesonide in COPD exacerbation Source: Annual Congress 2012 - COPD exacerbation Year: 2012 Aerosolized budesonide therapy in acute moderate exacerbations of Indian asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004 Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy of budesonide inhalation suspension in acute exacerbation of bronchial asthma in adults Source: Eur Respir J 2006; 28: Suppl. 50, 500s Year: 2006 Aerosolized fluticasone propionate therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014 Cardiovascular safety of high doses of the nebulized bronchodilators in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006